Correlation Between Ocular Therapeutix and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both Ocular Therapeutix and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ocular Therapeutix and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ocular Therapeutix and Molecular Partners AG, you can compare the effects of market volatilities on Ocular Therapeutix and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ocular Therapeutix with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ocular Therapeutix and Molecular Partners.
Diversification Opportunities for Ocular Therapeutix and Molecular Partners
0.3 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Ocular and Molecular is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding Ocular Therapeutix and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Ocular Therapeutix is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ocular Therapeutix are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Ocular Therapeutix i.e., Ocular Therapeutix and Molecular Partners go up and down completely randomly.
Pair Corralation between Ocular Therapeutix and Molecular Partners
Given the investment horizon of 90 days Ocular Therapeutix is expected to under-perform the Molecular Partners. But the stock apears to be less risky and, when comparing its historical volatility, Ocular Therapeutix is 1.89 times less risky than Molecular Partners. The stock trades about -0.3 of its potential returns per unit of risk. The Molecular Partners AG is currently generating about -0.08 of returns per unit of risk over similar time horizon. If you would invest 646.00 in Molecular Partners AG on August 28, 2024 and sell it today you would lose (84.00) from holding Molecular Partners AG or give up 13.0% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Ocular Therapeutix vs. Molecular Partners AG
Performance |
| Timeline |
| Ocular Therapeutix |
| Molecular Partners |
Ocular Therapeutix and Molecular Partners Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Ocular Therapeutix and Molecular Partners
The main advantage of trading using opposite Ocular Therapeutix and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ocular Therapeutix position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.| Ocular Therapeutix vs. CytomX Therapeutics | Ocular Therapeutix vs. Assembly Biosciences | Ocular Therapeutix vs. Spero Therapeutics | Ocular Therapeutix vs. Achilles Therapeutics PLC |
| Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Complementary Tools
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |